An alternative approach to antagonize the PD1/PDL1 axis is to use a soluble PD1 ectodomain acting as a ligand trap or decoy to neutralize PDL1-expressing cancer cells and therefore hijack the process of immune suppression by tumor cells (Stanczak et al. 2018). Here, PDCD1 is linked to cancer.